Uncategorized
Shire, Parion enter agreement for investigational dry eye treatment
Shire is purchasing the worldwide rights to Parion Sciences’ dry eye compound P-321 for $20 million, the companies announced in a press release.P-321, an epithelial sodium channel inhibitor, is a phase 2 investigational topical treatment. It was previously evaluated in a phase 1/2a study in 53 patients, and it targets tear volume deficiency and promotes ocular surface healing, the release said. It is different from other dry eye prescriptions on the market, which target the effects of ocular inflammation, because it blocks the absorption of tears to help keep the (Read more...)